Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia
- 1 November 2012
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 120 (18), 3670-3676
- https://doi.org/10.1182/blood-2012-06-438804
Abstract
Rozrolimupab, a recombinant mixture of 25 fully human RhD-specific monoclonal antibodies, represents a new class of recombinant human antibody mixtures. In a phase 1 or 2 dose escalation study, RhD+ patients (61 subjects) with primary immune thrombocytopenia received a single intravenous dose of rozrolimupab ranging from 75 to 300 μg/kg. The primary outcome was the occurrence of adverse events. The principal secondary outcome was the effect on platelet levels 7 days after the treatment. The most common adverse events were headache and pyrexia, mostly mild, and reported in 20% and 13% of the patients, respectively, without dose relationship. Rozrolimupab caused an expected transient reduction of hemoglobin concentration in the majority of the patients. At the dose of 300 μg/kg platelet responses, defined as platelet count ≥ 30 × 109/L and an increase in platelet count by > 20 × 109/L from baseline were observed after 72 hours and persisted for at least 7 days in 8 of 13 patients (62%). Platelet responses were observed within 24 hours in 23% of patients and lasted for a median of 14 days. Rozrolimupab was well tolerated and elicited rapid platelet responses in patients with immune thrombocytopenia and may be a useful alternative to plasma-derived products. This trial is registered at www.clinicaltrials.gov as #NCT00718692.Keywords
This publication has 26 references indexed in Scilit:
- Consistent manufacturing and quality control of a highly complex recombinant polyclonal antibody product for human therapeutic useBiotechnology & Bioengineering, 2011
- International consensus report on the investigation and management of primary immune thrombocytopeniaBlood, 2010
- Idiopathic thrombocytopenic purpura: Current concepts in pathophysiology and managementThrombosis and Haemostasis, 2008
- Efficacy and safety of intravenous anti-D immunoglobulin (Rhophylac®) in chronic immune thrombocytopenic purpuraHematology, 2007
- Extensive restrictions in the VH sequence usage of the human antibody response against the Rhesus D antigenMolecular Immunology, 2007
- Prevalence of immune thrombocytopenia: analyses of administrative dataJournal of Thrombosis and Haemostasis, 2006
- Single dose of anti-D immune globulin at 75μg/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in childrenThe Journal of Pediatrics, 2006
- Intravenous (IV) anti‐D and IV immunoglobulin achieve acute platelet increases by different mechanisms: modulation of cytokine and platelet responses to IV anti‐D by FcγRIIa and FcγRIIIa polymorphismsBritish Journal of Haematology, 2004
- Anti-D initially stimulates an Fc-dependent leukocyte oxidative burst and subsequently suppresses erythrophagocytosis via interleukin-1 receptor antagonistBlood, 2003
- Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpuraThe Lancet, 1994